{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:41:20Z","timestamp":1790178080821,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.kint.2024.05.024","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T23:05:52Z","timestamp":1718751952000},"page":"688-698","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["A meta-analysis of randomized controlled clinical trials for implications of acute treatment effects on glomerular filtration rate for long-term kidney protection"],"prefix":"10.1016","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3126-3730","authenticated-orcid":false,"given":"Hiddo J.L.","family":"Heerspink","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin","family":"Eddington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhi","family":"Chaudhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Estacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7018-7603","authenticated-orcid":false,"given":"Enyu","family":"Imai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian","family":"Goicoechea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8493-8260","authenticated-orcid":false,"given":"Thierry","family":"Hannedouche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Haynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tazeen H.","family":"Jafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5491-3460","authenticated-orcid":false,"given":"David W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob C.M.","family":"van Kruijsdijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia B.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9879-8388","authenticated-orcid":false,"given":"Philip K.T.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9276-8380","authenticated-orcid":false,"given":"Brendon L.","family":"Neuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4963-1132","authenticated-orcid":false,"given":"Ronald D.","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Ruggenenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9507-5301","authenticated-orcid":false,"given":"Christoph","family":"Wanner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley A.","family":"Inker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.kint.2024.05.024_bib1","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/s41591-023-02418-0","article-title":"A\u00a0meta-analysis of GFR slope as a surrogate endpoint for kidney failure","volume":"29","author":"Inker","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.kint.2024.05.024_bib2","article-title":"Qualification opinion for GFR Slope as a Validated Surrogate Endpoint for RCT in CKD","year":"2023","journal-title":"Committee for Medicinal Products for Human Use (CHMP)"},{"key":"10.1016\/j.kint.2024.05.024_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.ajkd.2019.08.007","article-title":"Change in estimated GFR and albuminuria as end points in clinical trials: a viewpoint from the FDA","volume":"75","author":"Thompson","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2024.05.024_bib4","doi-asserted-by":"crossref","first-page":"874","DOI":"10.2215\/CJN.00600206","article-title":"Surrogate end points for clinical trials of kidney disease progression","volume":"1","author":"Stevens","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.024_bib5","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1681\/ASN.2021070948","article-title":"Acute treatment effects on GFR in randomized clinical trials of kidney disease progression","volume":"33","author":"Neuen","year":"2022","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.024_bib6","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/ki.1997.111","article-title":"A\u00a0short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function","volume":"51","author":"Apperloo","year":"1997","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.05.024_bib7","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/ki.2011.79","article-title":"An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function","volume":"80","author":"Holtkamp","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2024.05.024_bib8","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1159\/000524889","article-title":"Initial eGFR changes with ertugliflozin and associations with clinical parameters: analyses from the VERTIS CV trial","volume":"53","author":"Cherney","year":"2022","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2024.05.024_bib9","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1053\/j.ajkd.2023.03.013","article-title":"Acute declines in estimated GFR in blood pressure target trials and risk of adverse outcomes","volume":"82","author":"Ku","year":"2023","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2024.05.024_bib10","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1681\/ASN.2018121261","article-title":"Implications of early decline in eGFR due to intensive BP control for cardiovascular outcomes in SPRINT","volume":"30","author":"Beddhu","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.024_bib11","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A\u00a0new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2024.05.024_bib12","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1053\/j.ajkd.2023.05.012","article-title":"Impact of using the race-free 2021 CKD-EPI creatinine equation on treatment effects on GFR-based endpoints in clinical trials","volume":"83","author":"Chaudhari","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2024.05.024_bib13","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1002\/sim.8282","article-title":"Mixed-effects models for slope-based endpoints in clinical trials of chronic kidney disease","volume":"38","author":"Vonesh","year":"2019","journal-title":"Stat Med"},{"key":"10.1016\/j.kint.2024.05.024_bib14","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","article-title":"GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"64","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2024.05.024_bib15","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1053\/j.ajkd.2014.08.017","article-title":"GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials","volume":"64","author":"Inker","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2024.05.024_bib16","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1053\/j.ajkd.2014.08.019","article-title":"Utility and validity of estimated GFR-based surrogate time-to-event end points in CKD: a simulation study","volume":"64","author":"Greene","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2024.05.024_bib17","series-title":"R: A Language and Environment for Statistical Computing","year":"2014"},{"key":"10.1016\/j.kint.2024.05.024_bib18","article-title":"RStan: the R interface to Stan","year":"2023","journal-title":"R\u00a0package"},{"key":"10.1016\/j.kint.2024.05.024_bib19","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1681\/ASN.2016060666","article-title":"Glomerular hyperfiltration in diabetes: mechanisms, clinical significance, and treatment","volume":"28","author":"Tonneijck","year":"2017","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.024_bib20","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1053\/j.ajkd.2013.09.016","volume":"63","author":"Heerspink","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2024.05.024_bib21","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1681\/ASN.2019010009","article-title":"Performance of GFR slope as a surrogate end point for kidney disease progression in clinical trials: a statistical simulation","volume":"30","author":"Greene","year":"2019","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.kint.2024.05.024_bib22","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.kint.2024.05.024_bib23","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.kint.2024.05.024_bib24","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes\u00a0with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2024.05.024_bib25","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.008983","article-title":"Letter by Inker et\u00a0al regarding article, \"pitfalls in using estimated glomerular filtration rate slope as a surrogate for the effect of drugs on the risk of serious adverse renal outcomes in clinical trials of patients with heart failure.\"","volume":"15","author":"Inker","year":"2022","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.kint.2024.05.024_bib26","first-page":"e57","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"386","author":"Heerspink","year":"2022","journal-title":"N\u00a0Engl J Med"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253824004058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253824004058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T07:49:41Z","timestamp":1728546581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253824004058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S0085253824004058"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2024.05.024","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A meta-analysis of randomized controlled clinical trials for implications of acute treatment effects on glomerular filtration rate for long-term kidney protection","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2024.05.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2024.07.023","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2024.06.007","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 International Society of Nephrology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}